BR0209594A - Inibidores de protease de hiv de amplo espectro de 2-amino-benzoxazol sulfonamida - Google Patents

Inibidores de protease de hiv de amplo espectro de 2-amino-benzoxazol sulfonamida

Info

Publication number
BR0209594A
BR0209594A BR0209594-7A BR0209594A BR0209594A BR 0209594 A BR0209594 A BR 0209594A BR 0209594 A BR0209594 A BR 0209594A BR 0209594 A BR0209594 A BR 0209594A
Authority
BR
Brazil
Prior art keywords
alkyl
protease inhibitors
cycloalkyl
hiv protease
amino
Prior art date
Application number
BR0209594-7A
Other languages
English (en)
Inventor
Dominique Louis Nest Surleraux
Sandrine Marie Hele Vendeville
Wim Gaston Verschueren
Marie-Pierre T M M G D Bethune
Herman Augustinus De Kock
Abdellah Tahri
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BR0209594A publication Critical patent/BR0209594A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"INIBIDORES DE PROTEASE DE HIV DE AMPLO ESPECTRO DE 2-AMINO-BENZOXAZOL SULFONAMIDA". A presente invenção refere-se a compostos tendo a fórmula (I), seus N-óxidos, sais, formas estereoisoméricas, misturas racêmicas, pró-drogas, ésteres e metabólitos, onde R1 e R8 são, cada um H, C~ 1-6~ alquila opcionalmente substituída, C~ 2-6~ alquenila, C~ 3-7~ cicloalquila, arila, Het^ 1^, Het^ 2^; R1 também pode ser um radical de fórmula (R11 aR11b)NC(R10aR10b)CR9-; t é 0,1 ou 2; R2 é H ou C~ 1-6~ alquila; L é -C(=O)-, -O-C(=O)-, -NR8-C(=O)-, -0-C1-6-alcanodiil-C(=O)-, -NR8-C1-6 alcanodiil-C(=O)-, -S(=0)2-, -OS(=0)2-, -NR8-S(=0)2; R3 é C1-6 alquila, arila, C3-7 cicloalquila, C3-7 ciclo-alquil C1-4 alquila, ou aril C1-4 alquila; R4 é H, C1-4 alquil OC(=O), carboxila, aminoC(=O), mono- ou di(Cl-4 alquil) aminoC(=O), C3-7 cicloalquila, C2-6 alquenila, C2-6 alquinila ou C1-6 alquila opcionalmente substituída; R5 e R6 são H ou C1-6 alquila. Ela ainda refere-se a seu uso como inibidores de protease de HIV de amplo espectro, processo para sua preparação assim como composições farmacêuticas e kits diagnósticos compreendendo os mesmos. Ela também refere-se a suas combinações com outros agentes anti-retrovirais, e a seu uso em ensaios como compostos de referência ou como reagentes.
BR0209594-7A 2001-05-11 2002-05-10 Inibidores de protease de hiv de amplo espectro de 2-amino-benzoxazol sulfonamida BR0209594A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201732 2001-05-11
PCT/EP2002/005212 WO2002092595A1 (en) 2001-05-11 2002-05-10 Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
BR0209594A true BR0209594A (pt) 2004-03-30

Family

ID=8180286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209594-7A BR0209594A (pt) 2001-05-11 2002-05-10 Inibidores de protease de hiv de amplo espectro de 2-amino-benzoxazol sulfonamida

Country Status (32)

Country Link
US (2) US7622490B2 (pt)
EP (1) EP1387842B1 (pt)
JP (1) JP4467889B2 (pt)
KR (1) KR100878853B1 (pt)
CN (1) CN100549007C (pt)
AP (1) AP1652A (pt)
AR (1) AR035970A1 (pt)
AT (1) ATE429431T1 (pt)
AU (1) AU2002310818B2 (pt)
BG (1) BG66350B1 (pt)
BR (1) BR0209594A (pt)
CA (1) CA2444895C (pt)
CY (1) CY1109247T1 (pt)
CZ (1) CZ304524B6 (pt)
DE (1) DE60232067D1 (pt)
DK (1) DK1387842T3 (pt)
EA (1) EA009590B1 (pt)
EE (1) EE05307B1 (pt)
ES (1) ES2325809T3 (pt)
HK (1) HK1062912A1 (pt)
HR (1) HRP20031026B1 (pt)
HU (1) HUP0400438A3 (pt)
IL (1) IL158093A0 (pt)
MX (1) MXPA03010258A (pt)
NO (1) NO326883B1 (pt)
NZ (1) NZ529250A (pt)
OA (1) OA13134A (pt)
PL (1) PL209029B1 (pt)
PT (1) PT1387842E (pt)
SK (1) SK287952B6 (pt)
WO (1) WO2002092595A1 (pt)
ZA (1) ZA200307799B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1483254A4 (en) 2002-01-07 2005-06-08 Sequoia Pharmaceuticals INHIBITORS OF ANTI-RESISTANCE RETROVIRAL PROTEASE
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EA011891B1 (ru) * 2003-09-30 2009-06-30 Тиботек Фармасьютикалз Лтд. Способы получения соединений бензоксазолсульфонамида и их промежуточные соединения
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
JP4818124B2 (ja) 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド （３Ｒ，３ａＳ，６ａＲ）−ヘキサヒドロフロ〔２，３−ｂ〕フラン−３−イル（１Ｓ，１Ｒ）−３−〔〔（４−アミノフェニル）スルホニル〕（イソブチル）アミノ〕−１−ベンジル−２−ヒドロキシプロピルカルバマートの製造方法
EP1725566B1 (en) 2003-12-23 2009-06-17 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
AU2005244121B2 (en) * 2004-05-07 2012-01-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
KR101333627B1 (ko) 2005-02-25 2013-11-27 얀센 알 앤드 디 아일랜드 프로테아제 저해제 전구체 합성
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
ATE141635T1 (de) 1990-03-09 1996-09-15 Milliken Res Corp Organische materialien, die sulfonamidogebundene poly(oxyalkylen)gruppen tragen und ihre herstellung
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR100296461B1 (ko) * 1992-08-25 2001-11-14 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한n-(알카노일아미노-2-히드록시프로필)-술폰아미드
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
DE69429357T2 (de) 1993-10-01 2002-08-14 Astrazeneca Ab, Soedertaelje Verfahren i
CA2210889C (en) 1995-01-20 2007-08-28 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
DE69625183T2 (de) 1995-03-10 2003-10-09 G.D. Searle & Co., Chicago Heterocyclocarbonyl-aminosäure-hydroxyethylamino-sulfonamid inhibitoren retroviraler proteasen
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
HU227745B1 (en) 1996-05-20 2012-02-28 Janssen Pharmaceutica Nv Antifungal compositions containing itraconazole
BR9806174A (pt) 1997-03-26 1999-10-19 Janssen Pharmaceutica Nv Péletes tendo um núcleo revestido com um antifúngico e um polìmero
GB9717849D0 (en) 1997-08-23 1997-10-29 Seal Sands Chemicals Limited Preparation of pyridene derivatives
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
TR200002402T2 (tr) 1997-12-24 2001-01-22 Vertex Pharmaceuticals Incorporated Aspartil proteaz inhibitörü ön-ilaçlar.
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
AR035819A1 (es) * 2001-04-09 2004-07-14 Tibotec Pharm Ltd 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos

Also Published As

Publication number Publication date
IL158093A0 (en) 2004-03-28
PT1387842E (pt) 2009-07-20
KR100878853B1 (ko) 2009-01-15
AP1652A (en) 2006-08-11
DE60232067D1 (de) 2009-06-04
PL209029B1 (pl) 2011-07-29
CA2444895A1 (en) 2002-11-21
NZ529250A (en) 2005-05-27
NO20034988D0 (no) 2003-11-10
CY1109247T1 (el) 2014-07-02
NO326883B1 (no) 2009-03-09
CZ20033290A3 (cs) 2004-05-12
US7863306B2 (en) 2011-01-04
EE200300547A (et) 2004-02-16
CA2444895C (en) 2011-02-15
ZA200307799B (en) 2005-03-30
ES2325809T3 (es) 2009-09-18
CZ304524B6 (cs) 2014-06-18
PL366780A1 (en) 2005-02-07
CN100549007C (zh) 2009-10-14
JP4467889B2 (ja) 2010-05-26
MXPA03010258A (es) 2005-03-07
EA200301234A1 (ru) 2004-04-29
US20040106661A1 (en) 2004-06-03
US7622490B2 (en) 2009-11-24
BG108309A (bg) 2004-12-30
EA009590B1 (ru) 2008-02-28
EE05307B1 (et) 2010-06-15
SK14902003A3 (sk) 2004-07-07
AR035970A1 (es) 2004-07-28
EP1387842B1 (en) 2009-04-22
JP2004534757A (ja) 2004-11-18
WO2002092595A1 (en) 2002-11-21
HRP20031026B1 (en) 2012-07-31
HK1062912A1 (en) 2004-12-03
OA13134A (en) 2006-12-13
DK1387842T3 (da) 2009-08-10
BG66350B1 (bg) 2013-08-30
CN1507446A (zh) 2004-06-23
EP1387842A1 (en) 2004-02-11
HRP20031026A2 (en) 2005-10-31
AU2002310818B2 (en) 2007-12-13
ATE429431T1 (de) 2009-05-15
SK287952B6 (sk) 2012-06-04
US20100029632A1 (en) 2010-02-04
KR20040022417A (ko) 2004-03-12
HUP0400438A3 (en) 2007-08-28
HUP0400438A2 (hu) 2004-08-30
AP2003002904A0 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
BR0209594A (pt) Inibidores de protease de hiv de amplo espectro de 2-amino-benzoxazol sulfonamida
BR0207862A (pt) Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro
AR064492A1 (es) Derivados de isoquinolona sustituidos con cicloalquilamina
BRPI0606319A2 (pt) compostos farmacêuticos
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
EA199900907A1 (ru) 4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич
IS7555A (is) Non neucleside hindrar fyrir víxlrita
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
BRPI0514606A (pt) sais de lercanidipina
BR0309397A (pt) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia
BRPI0512615A (pt) compostos de sulfonamida
ES2189726T3 (es) Isoxazolidinas sustituidas con heterociclo y su uso como fungicidas.
BRPI0515121A (pt) derivados da n-2 adamantil-2-fenóxi acetamida como inibidores da 11-beta hidroxiesteróide desidrogenase
HRP20050606B1 (hr) Supstituirani oksindol sulfonamid hiv proteazni inhibitori širokog spektra
CY1112971T1 (el) Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
ATE401326T1 (de) Oxazolidinon-chinolon hybrid antibiotika
ATE511500T1 (de) Sulfonamide als orexin-antagonisten
UY27263A1 (es) Nuevas arilsulfonamidas como agentes antivirales
BR0208796A (pt) Inibidores 2-(amino substituìdo)-benzoxazol sulfonamida hiv protease de amplo espectro
SV2003000995A (es) Nuevas arilsulfonamidas como agentes antivirales ref. lea35214-sv
BR0310089A (pt) Inibidores de protease de hiv de sulfonamida benzisoxazol substituìda de largo espectro
BRPI0417007A (pt) agentes antivirais de diazaindol-dicarbonil-piperazinila
BR0308588A (pt) Inibidores de entrada de molécula pequena
TH85263A (th) สารยับยั้ง hiv โปรติเอส ที่เป็นเบนซิโซซาโซล ซัลโฟนามีด ที่ถูกแทนที่ สเปกตรัมกว้าง

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 513/12, C07D 493/04, C07D 417/12, C07D 263/58, C07D 498/04, C07D 513/04, C07D 413/14, C07D 417/14, A61K 31/423, C07D 491/04

Ipc: C07D 413/12 (2011.01), C07D 493/04 (2011.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.